Table 3.
Treatment and clinical course of patients
| Patient no. | First treatment (cycle or Gy) | Time to progression, mon | Salvage treatment (cycle or Gy) | Clinical course after salvage treatment | Overall survival, mon | Survival status |
|---|---|---|---|---|---|---|
| #1 | HyperCVAD (#6) → CR → PD (leukemic transformation) | 19 | VPDL (#1) → PR → PD | Disease progression in CNS | 23 | Dead |
| #2 | HyperCVAD (#6) + RT (40 Gy) → PR → PD | 6 | SMILE (#1) → PD → DHAP (#2) →PD → GDP (#2) → PD | MEC chemotherapy → CR | 25 | Alive |
| #3 | VPDL (#3) → CR → PD | 11 | RT (40 Gy) → PR → GDP (#3) → CR | Ongoing chemotherapy | 20 | Alive |
| #4 | Not done | NA | NA | NA | 6 | Dead |
| #5 | VIDL (#2) → CR → PD | 3 | RT (30 Gy) → PD | GDP (#2) → PD | 6 | Dead |
| #6 | VPDL (#2) → PR → PD | 4 | SMILE (#2) → PR | Ongoing chemotherapy | 9 | Alive |
| #7 | HyperCVAD (#4) + Allo-SCT → CR → PD | 14 | GDP (#4) → PR → PD | VIDL → PR | 24 | Alive |
| #8 | HyperCVAD (#2) → CR → PD | 7 | ESHAOX (#4) + Auto-SCT → CR → PD | MEC chemotherapy → PD | 18 | Dead |
| #9 | RT (21 Gy) → PR → PD | 2 | RT (36 Gy) → SD → PD | IA chemotherapy | 19 | Alive |
| #10 | CHOP (#6) → PR → PD | 12 | DHAP (#2) → PD → CALGB + Allo-SCT → CR | Chronic GVHD with pneumonia during follow-up → Death | 34 | Dead |
Gy, gray; HyperCVAD, alternate cycles of hyperfractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone, and methotrexate, cytarabine; CR, complete response; PD, progression disease; VPDL, vincristine, methylprednisolone, daunorubicin, L-asparaginase; PR, partial response; CNS, central nervous system; RT, radiation therapy; SMILE, methotrexate, etoposide, ifospamide, dexamethasone, L-asparaginase; DHAP, cisplatin, cytarabine, dexamethasone; GDP, gemcitabine, dexamethasone, cisplatin; MEC, mitoxantrone, etoposide, cytarabine; NA, not applicable; VIDL, vincristine, etoposide, ifosfamide, dexamethasone; Allo-SCT, allogenic stem cell transplantation; ESHAOX, etoposide, methylprednisolone, oxaliplatin, cytarabine; Auto-SCT, autologous stem cell transplantation; SD, stable disease; IA, idarubicin, cytarabine; CHOP, doxorubicin, cyclophosphamide, vincristine, prednisone; CALGB, cyclophosphamide, daunorubicin, vincristine, prednisone; GVHD, graftversus-host disease.